Peter Smith
Directeur/Membre du Conseil chez RYVU THERAPEUTICS S.A.
Postes actifs de Peter Smith
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| RYVU THERAPEUTICS S.A. | Directeur/Membre du Conseil | 14/06/2023 | - |
Remix Therapeutics, Inc.
 Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Directeur Général | 17/08/2021 | - |
| Fondateur | - | - | |
| President | - | - | |
| Directeur Technique/Scientifique/R&D | - | 17/08/2021 | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | 01/01/2018 | - |
Amplify Medicines, Inc.
 Amplify Medicines, Inc. Pharmaceuticals: GenericHealth Technology Part of Ikena Oncology, Inc., Amplify Medicines, Inc. develops pharmaceutical drugs. The company is based in Boston, MA. The company was founded by Peter Smith. | Directeur Technique/Scientifique/R&D | - | - |
| Fondateur | - | - |
Historique de carrière de Peter Smith
Anciens postes connus de Peter Smith
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | 01/01/2011 | 31/12/2018 |
Formation de Peter Smith
| Newcastle University | Doctorate Degree |
| University of Sheffield Medical School | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| Royaume-Uni | 3 |
| Pologne | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
| Chief Executive Officer | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| RYVU THERAPEUTICS S.A. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Amplify Medicines, Inc.
Amplify Medicines, Inc. Pharmaceuticals: GenericHealth Technology Part of Ikena Oncology, Inc., Amplify Medicines, Inc. develops pharmaceutical drugs. The company is based in Boston, MA. The company was founded by Peter Smith. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Bourse
- Insiders
- Peter Smith
- Expérience
